Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7KE2

Crystal structure of Staphylococcus aureus ketol-acid reductoisomerase in complex with Mg2+ and NSC116565

7KE2 の概要
エントリーDOI10.2210/pdb7ke2/pdb
分子名称Ketol-acid reductoisomerase (NADP(+)), MAGNESIUM ION, 6-hydroxy-2-methyl[1,3]thiazolo[4,5-d]pyrimidine-5,7(4H,6H)-dione, ... (4 entities in total)
機能のキーワードreductoisomerase, inhibitor, metal binding protein, isomerase, oxidoreductase
由来する生物種Staphylococcus aureus
タンパク質・核酸の鎖数2
化学式量合計76268.88
構造登録者
Kurz, J.L.,Patel, K.P.,Guddat, L.W. (登録日: 2020-10-09, 公開日: 2021-07-14, 最終更新日: 2023-10-18)
主引用文献Lin, X.,Kurz, J.L.,Patel, K.M.,Wun, S.J.,Hussein, W.M.,Lonhienne, T.,West, N.P.,McGeary, R.P.,Schenk, G.,Guddat, L.W.
Discovery of a Pyrimidinedione Derivative with Potent Inhibitory Activity against Mycobacterium tuberculosis Ketol-Acid Reductoisomerase.
Chemistry, 27:3130-3141, 2021
Cited by
PubMed Abstract: New drugs aimed at novel targets are urgently needed to combat the increasing rate of drug-resistant tuberculosis (TB). Herein, the National Cancer Institute Developmental Therapeutic Program (NCI-DTP) chemical library was screened against a promising new target, ketol-acid reductoisomerase (KARI), the second enzyme in the branched-chain amino acid (BCAA) biosynthesis pathway. From this library, 6-hydroxy-2-methylthiazolo[4,5-d]pyrimidine-5,7(4H,6H)-dione (NSC116565) was identified as a potent time-dependent inhibitor of Mycobacterium tuberculosis (Mt) KARI with a K of 95.4 nm. Isothermal titration calorimetry studies showed that this inhibitor bound to MtKARI in the presence and absence of the cofactor, nicotinamide adenine dinucleotide phosphate (NADPH), which was confirmed by crystal structures of the compound in complex with closely related Staphylococcus aureus KARI. It is also shown that NSC116565 inhibits the growth of H37Ra and H37Rv strains of Mt with MIC values of 2.93 and 6.06 μm, respectively. These results further validate KARI as a TB drug target and show that NSC116565 is a promising lead for anti-TB drug development.
PubMed: 33215746
DOI: 10.1002/chem.202004665
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.59 Å)
構造検証レポート
Validation report summary of 7ke2
検証レポート(詳細版)ダウンロードをダウンロード

250059

件を2026-03-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon